Oncogenex Pharmaceuticals Inc (OGXI) 2.06 $OGXI
OncoGenex Announces Relocation of Corporate Headquarters, Expected to Yield Savings of at Least $4 Million Over Next Three Years
CNW Group - Thu Feb 12, 4:45PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed new lease agreements enabling the relocation of its Bothell, Washington headquarters.
OGXI: 2.06 (-0.05)
OncoGenex's AFFINITY on Track, Passes Futility Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 3:10PM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the phase III AFFINITY study on custirsen has passed the interim futility analysis.
LCI: 57.78 (-0.91), ENDP: 84.01 (+1.12), OGXI: 2.06 (-0.05), TEVA: 56.77 (-0.58)
OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
CNW Group - Fri Jan 16, 5:30AM CST
AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis
OGXI: 2.06 (-0.05)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 02, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACC: 43.30 (-0.25), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), OGXI: 2.06 (-0.05), GILD: 101.90 (+1.10), ONVO: 6.34 (+0.07), TKMR: 21.45 (-0.22), TEVA: 56.77 (-0.58), MDXG: 8.65 (+0.23)
OncoGenex to End Deal with Teva & Regain Custirsen Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:55PM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) executed an initial agreement to regain all rights to custirsen from Teva and end collaboration agreement with the company.
LCI: 57.78 (-0.91), OGXI: 2.06 (-0.05), APRI: 1.84 (-0.08), TEVA: 56.77 (-0.58)
Daily Pharma Dose: New Research on Hospira, Aquinox, Sucampo, NephroGenex and OncoGenex
PR Newswire - Wed Dec 31, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AQXP: 10.29 (-0.54), OGXI: 2.06 (-0.05), NRX: 6.67 (-0.14), SCMP: 15.32 (+0.04), HSP: 87.35 (unch)
OncoGenex and Teva cut ties on custirsen development
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 8:22AM CST
OGXI: 2.06 (-0.05), TEVA: 56.77 (-0.58)
OncoGenex to Regain Rights to Custirsen from Teva
CNW Group - Tue Dec 30, 6:00AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers. This transfer of rights would occur in connection with the termination of the collaboration agreement between OncoGenex and Teva executed in 2009.
OGXI: 2.06 (-0.05), TEVA: 56.77 (-0.58)
Traders Get Bullish on Shares of OncoGenex Pharmaceutical, Shares Up 5.1% (OGXI)
Comtex SmarTrend(R) - Fri Dec 26, 10:35AM CST
OncoGenex Pharmaceutical (NASDAQ:OGXI) is one of today's best performing low-priced stocks, up 5.1% to $2.21 on 1.1x average daily volume. OncoGenex Pharmaceutical has traded 275,000 shares thus far today, vs. average volume of 254,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's 0.2%) and outperformed the S&P 500 (5.1% to the S&P's 0.4%) during today's trading.
OGXI: 2.06 (-0.05)
Value Remains At OncoGenex After Borealis-1
Daniel Ward - at Seeking Alpha - Fri Dec 26, 8:00AM CST
OGXI: 2.06 (-0.05)
OncoGenex cancer drug reduces risk of death in metastatic bladder cancer
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:05AM CST
OGXI: 2.06 (-0.05)
OncoGenex Announces Results from the Phase 2 Borealis-1(TM) Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer
PR Newswire - Fri Dec 19, 7:00AM CST
Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with Lower Performance Status
OGXI: 2.06 (-0.05)
OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 2:10PM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) has completed enrolling patients in its phase II Rainier study on apatorsen for previously untreated metastatic pancreatic cancer.
LCI: 57.78 (-0.91), OGXI: 2.06 (-0.05), PFE: 34.64 (-0.23), NVS: 102.20 (-0.17)
OncoGenex Announces Completion of Patient Enrollment in the Rainier(TM) Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
CNW Group - Tue Dec 16, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the RainierTM clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with ABRAXANE(®) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Rainier is sponsored and led by the Sarah Cannon Research Institute (SCRI) and is being conducted at 11 sites in the United States.
OGXI: 2.06 (-0.05)
OncoGenex Announces Relocation of Corporate Headquarters, Expected to Yield Savings of at Least $4 Million Over Next Three Years
CNW Group - Thu Feb 12, 4:45PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed new lease agreements enabling the relocation of its Bothell, Washington headquarters.
OGXI: 2.06 (-0.05)
OncoGenex's AFFINITY on Track, Passes Futility Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 3:10PM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the phase III AFFINITY study on custirsen has passed the interim futility analysis.
LCI: 57.78 (-0.91), ENDP: 84.01 (+1.12), OGXI: 2.06 (-0.05), TEVA: 56.77 (-0.58)
OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
CNW Group - Fri Jan 16, 5:30AM CST
AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis
OGXI: 2.06 (-0.05)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 02, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACC: 43.30 (-0.25), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), OGXI: 2.06 (-0.05), GILD: 101.90 (+1.10), ONVO: 6.34 (+0.07), TKMR: 21.45 (-0.22), TEVA: 56.77 (-0.58), MDXG: 8.65 (+0.23)
OncoGenex to End Deal with Teva & Regain Custirsen Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:55PM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) executed an initial agreement to regain all rights to custirsen from Teva and end collaboration agreement with the company.
LCI: 57.78 (-0.91), OGXI: 2.06 (-0.05), APRI: 1.84 (-0.08), TEVA: 56.77 (-0.58)
Daily Pharma Dose: New Research on Hospira, Aquinox, Sucampo, NephroGenex and OncoGenex
PR Newswire - Wed Dec 31, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AQXP: 10.29 (-0.54), OGXI: 2.06 (-0.05), NRX: 6.67 (-0.14), SCMP: 15.32 (+0.04), HSP: 87.35 (unch)
OncoGenex and Teva cut ties on custirsen development
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 8:22AM CST
OGXI: 2.06 (-0.05), TEVA: 56.77 (-0.58)
OncoGenex to Regain Rights to Custirsen from Teva
CNW Group - Tue Dec 30, 6:00AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers. This transfer of rights would occur in connection with the termination of the collaboration agreement between OncoGenex and Teva executed in 2009.
OGXI: 2.06 (-0.05), TEVA: 56.77 (-0.58)
Traders Get Bullish on Shares of OncoGenex Pharmaceutical, Shares Up 5.1% (OGXI)
Comtex SmarTrend(R) - Fri Dec 26, 10:35AM CST
OncoGenex Pharmaceutical (NASDAQ:OGXI) is one of today's best performing low-priced stocks, up 5.1% to $2.21 on 1.1x average daily volume. OncoGenex Pharmaceutical has traded 275,000 shares thus far today, vs. average volume of 254,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's 0.2%) and outperformed the S&P 500 (5.1% to the S&P's 0.4%) during today's trading.
OGXI: 2.06 (-0.05)
Value Remains At OncoGenex After Borealis-1
Daniel Ward - at Seeking Alpha - Fri Dec 26, 8:00AM CST
OGXI: 2.06 (-0.05)
OncoGenex cancer drug reduces risk of death in metastatic bladder cancer
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:05AM CST
OGXI: 2.06 (-0.05)
OncoGenex Announces Results from the Phase 2 Borealis-1(TM) Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer
PR Newswire - Fri Dec 19, 7:00AM CST
Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with Lower Performance Status
OGXI: 2.06 (-0.05)
OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 2:10PM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) has completed enrolling patients in its phase II Rainier study on apatorsen for previously untreated metastatic pancreatic cancer.
LCI: 57.78 (-0.91), OGXI: 2.06 (-0.05), PFE: 34.64 (-0.23), NVS: 102.20 (-0.17)
OncoGenex Announces Completion of Patient Enrollment in the Rainier(TM) Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
CNW Group - Tue Dec 16, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the RainierTM clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with ABRAXANE(®) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Rainier is sponsored and led by the Sarah Cannon Research Institute (SCRI) and is being conducted at 11 sites in the United States.
OGXI: 2.06 (-0.05)
